Show simple item record

dc.contributor.authorPilar Cuellar, María Fuencisla
dc.contributor.authorCastro Fernández, María Elena 
dc.contributor.authorBretin, Sylvie
dc.contributor.authorMocaer, Elisabeth
dc.contributor.authorPazos Carro, Ángel 
dc.contributor.authorDíaz Martínez, Álvaro 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2019-06-21T15:05:17Z
dc.date.issued2019-07
dc.identifier.issn0278-5846
dc.identifier.issn1878-4216
dc.identifier.otherSAF2015-67457-Res_ES
dc.identifier.urihttp://hdl.handle.net/10902/16377
dc.description.abstractS 47445 is a positive allosteric modulator of glutamate AMPA-type receptors that possesses procognitive, neurotrophic and enhancing synaptic plasticity properties. Its chronic administration promotes antidepressant- and anxiolytic-like effects in different rodent models of depression. We have evaluated the behavioral effects of S 47445 in the bilateral olfactory bulbectomy mice model (OB) and the adaptive changes in those proteins associated to brain neuroplasticity (BDNF and mTOR pathway). Following OB surgery, adult C57BL/6J male mice were chronically administered S 47445 (1, 3 and 10?mg/kg/day; i.p.) and fluoxetine (18?mg/kg/day; i.p.), and then behaviorally tested in the open field test. Afterwards, the expression levels of BDNF, mTOR, phospho-mTOR, 4EBP1 and phospho-4EBP1 were evaluated in hippocampus and prefrontal cortex. Both drugs reduced the OB-induced locomotor activity, a predictive outcome of antidepressant efficacy, with a similar temporal pattern of action. S 47445, but not fluoxetine, showed an anxiolytic effect as reflected by an increased central activity. Chronic administration of S 47445 reversed OB-induced changes in BDNF and phopho-mTOR expression in hippocampus but not in prefrontal cortex. The chronic administration of S 47445 induced antidepressant- and anxiolytic-like effects at low-medium doses (1 and 3?mg/kg/day, i.p.) associated with the reversal of OB-induced changes in hippocampal BDNF and mTOR signaling pathways.es_ES
dc.description.sponsorshipFunding: This work was supported by the Institut de Recherches Internationales Servier and the Spanish Ministry of Economy and Competitiveness (MINECO/FEDER) (grant number SAF2015-67457-R).es_ES
dc.format.extent9 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceProg Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:205-213es_ES
dc.subject.otherAMPA Positive Allosteric Modulatores_ES
dc.subject.otherBDNFes_ES
dc.subject.otherDepressiones_ES
dc.subject.otherNeuroplasticityes_ES
dc.subject.othermTOR Pathwayes_ES
dc.titleS 47445 counteracts the behavioral manifestations and hippocampal neuroplasticity changes in bulbectomized micees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.pnpbp.2019.04.005es_ES
dc.rights.accessRightsembargoedAccesses_ES
dc.identifier.DOI10.1016/j.pnpbp.2019.04.005
dc.type.versionacceptedVersiones_ES
dc.date.embargoEndDate2020-07-01


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 licenseExcept where otherwise noted, this item's license is described as © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license